They are growing in number and challenging to treat not only because of the multiple complex factors that impact cancer in senior adults but also because of the lack of relevant and robust clinical trial data. Results of a multicenter sequential randomized clinical trial.Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.Single vs double autologous stem-cell transplantation for multiple myeloma [see comment].High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.A comparison of allografting with autografting for newly diagnosed myeloma.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.Melphalan and prednisone plus thalidomide vs melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.VAD-based regimens as primary treatment for multiple myeloma.Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone vs dexamethasone alone as primary therapy for newly diagnosed multiple myeloma [abstract].Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.A randomized phase III trial of lenalidomide plus high-dose dexamethasone vs lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract].Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.VELCADE/dexamethasone (Vel/Dex) vs VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial [abstract].Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM).

Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer InstituteInstitute for Advanced Studies in Aging and Geriatric MedicineDivision of Hematology and Oncology, University of MarylandDivision of Geriatric Medicine, University of Illinois College of MedicineCenter on Aging and Health, Johns Hopkins UniversityDepartment of Social and Preventive Medicine, Roswell Park Cancer Institute, University of Buffalo, Roswell Park Cancer Institute People do not usually have symptoms until they reach stage 3. Researchers believe that changes in DNA (doctors call them mutations) make plasma cells turn cancerous. Department of Health and Human Services Office of Minority Health: "Obesity and African-Americans.

Search for other works by this author on: 2018 Jun;93(6):810-815. doi: 10.1002/ajh.25098. Multiple myeloma is uncommon in young persons. Some of the most important advances are the advent of bisphosphonates to treat hypercalcemia and to prevent myeloma bone disease, the use of vertebroplasty and kyphoplasty to treat vertebral fractures, and judicious use of prophylactic antibiotics in selected patients.This work was supported in part the by the National Cancer Institute, Bethesda, MD (grants CA62242, CA85818, CA93842, and CA100080).Contribution: R.A.K. Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial [abstract].Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network.Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study.Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.